Inhaled Budesonide for Adults (50 Years and Over) – 'first COVID-19 treatment for use in the UK within a community setting'

Inhaled budesonide is not currently being recommended as standard of care but can be considered (off-label) on a case-by-case basis for symptomatic COVID-19 positive patients aged 65 and over, or aged 50 or over with co-morbidities.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date
Register

Existing members Sign in